Skip to content

Michael Liebrenz

5 papers in the library · 158 citations · publishing 2007-2026

Papers

Sort Most recent Most cited

‘Worthy doctors […] allow me to come forward and lecture on this matter’: Thomas De Quincey and the experiential and sociocultural components of substance use

BJPsych Bulletin May 4, 2026 Nicholas Griffin, Alexander H. Smith, Michael Liebrenz

Summary This article highlights the relevance of the humanities to psychiatric discussions. It considers Thomas De Quincey’s autobiographical Confessions of an English Opium-Eater (1821), where the author charts his opium experiences and dependence. The text provides an intersection of subjective and objective evaluations of drug use, and records experiences undertaken before establishment of...

DOI: 10.1192/bjb.2026.10245 (opens in new tab) Full text (opens in new tab) Relevance law Creativity Sociocultural evolution Experiential learning +7

Patient’s Perceptions of the Cannabis-psychosis Link - A Systematic Review

Current Pharmaceutical Design September 12, 2012 Anna Buadze, Stefan Kaiser, Rudolf Stohler et al. 10 citations

Over the past years a growing research effort has investigated the relation between cannabis use and schizophrenia at a neurobiological, epidemiological and clinical level. A number of systematic reviews and meta analyses have summarized the available evidence in the field. Conversely the patient's perception of the link between cannabis use and psychosis has been under investigation. Since...

Do patients think cannabis causes schizophrenia? - A qualitative study on the causal beliefs of cannabis using patients with schizophrenia.

Harm Reduction Journal September 28, 2010 Anna Buadze, Rudolf Stohler, Beate Schulze et al.

There has been a considerable amount of debate among the research community whether cannabis use may cause schizophrenia and whether cannabis use of patients with schizophrenia is associated with earlier and more frequent relapses. Considering that studies exploring patients' view on controversial topics have contributed to our understanding of important clinical issues, it is surprising how...

Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression

The World Journal of Biological Psychiatry May 12, 2008 Michael Liebrenz, Rudolf Stohler, Alain Borgeat 73 citations

BACKGROUND: The intravenous administration of ketamine, an N-methyl-D-aspartate receptor antagonist, results in a great improvement of depression symptoms, but it is not clear for how long. This single-case trial was conducted to explore the duration of improvement and the effects of a second administration on the clinical outcome. METHODS: In an open label trial, a 55-year-old male patient...

Intravenous ketamine therapy in a patient with a treatment-resistant major depression

Swiss Medical Weekly April 21, 2007 Michael Liebrenz, Alain Borgeat, R Leisinger 75 citations

BACKGROUND: Recently, reports from North America have indicated that the intravenous infusion of ketamine hydrochloride (an N-methyl-d-aspartate receptor antagonist) results in a sudden and robust improvement of depression symptoms. OBJECTIVE: To corroborate antidepressant effectiveness of IV ketamine in a patient with a co-occurring substance use disorder for the first time in a European...